Effects of Pamidronate Treatment on Osteogenesis Imperfecta
골형성부전증 환자에서 파미드로네이트의 치료 효과
이, 승원; 김, 현주; 조, 재현; 이, 형숙; 정, 연무; 김, 대중; 이, 관우; 정, 윤석
Journal of Korean Society of Endocrinology, 19(5):485-491, 2004
Journal of Korean Society of Endocrinology; 대한내분비학회지
Background:Osteogenesis imperfecta (OI) is a congenital disorder of type I collagen, with variable phenotypes, due to increased bone fragility and low bone mass. Previous pharmacological treatments for OI have been attempted with calcitonin and growth hormone but with little beneficial effects. Recently, Glorieux reported the beneficial effects of bisphosphonates in OI.
Methods:In this study, the effects of pamidronate treatment were evaluated in 9 patients with OI. All patients received intravenous pamidronate infusions, which was dose adjusted according to the patients’ age. The outcome measures included the biochemical bone markers; serum alkaline phosphatase, urine deoxy-pyridinoline, urine Ca/Cr ratio, and bone mineral density (BMD).
Results:Serum alkaline phosphatase, urine deoxypyridinoline, and urine Ca/Cr ratio were slightly decreased after 1 year of therapy, although these changes were not statistically significant. The BMDs of the lumbar spine and proximal femur were significantly increased after 1-year of pamidronate treatment. No fractures were reported during the 1 year treatment periods.
Conclusions:Pamidronate treatment had an effect on the BMD in osteogenesis imperfecta, probably due to decreasing bone resorption
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
Total Visit :3,092,276
Total Download :1,261,860
Today View :178
Ajou University Medical Information & Media Center 164 Worldcup-ro Yeongtong-gu Suwon 16499 Korea / TEL : 031-219-5312 / FAX : 031-219-5314 Copyright (c) Ajou University Medical Information & Media Center All Rights Reserved. AJOU Open Repository는 국립중앙도서관 OAK 보급사업으로 구축되었습니다.